Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial
Jun Ni,Huisheng Chen,Guofang Chen,Yong Ji,Fei Yi,Zhuobo Zhang,Yi Yang,Jin Wu,Xueli Cai,Bei Shao,Jianfeng Wang,Yafang Liu,Deqin Geng,Xinhui Qu,Xiaohong Li,Yan Wei,Jianping Ding,Hua Lü,Yining Huang,Yonghua Huang,Bo Xiao,Tao Gong,Liying Cui,study collaboration group,Dong Wang,Shugen Han,Xiaoping Gao,Xiaorong Zhuang,Guojun Tan,Runxiu Zhu,Hongye Bi,Hong Yang,Youqing Deng,Jinghua Zhou,Shengzhe Zheng,Zhiyong Wang,Xiaodong Lu,Juntao Li,Lina Huang,Weimin Hu,Dawei Zang,Xiaoxi Yao,Li Li,Liandong Zhao,Luoqing Li,Shifang Wang,Kaifu Ke,Tianming Lu,Qilin Ma,Qing Zhang,Baojun Wang,Liang Zhao,Hongliang Dong,Wei Gao,Ying Liu,Yamei Tang,Junfeng Gao,Xiaofei Yu,Libin Guo,Haiyan Lin,Xiue Wei,Chenglin Tian,Tong Zhang,Yaguo Li,Guoqiang Wen,Chengfang Zhou,Qi Fang
DOI: https://doi.org/10.1186/s12883-020-01844-8
2020-07-14
Abstract:Background: Ischemic stroke is a leading cause of morbidity and mortality. Thrombolytic therapy improves disability and survival rates; however, to be effective, it must be given within 4.5 h of onset. Moreover, thrombolytic therapy is frequently contraindicated. Therefore, alternative therapeutic options are required. In China, cinepazide maleate injection has been shown to improve the cerebral collateral circulation and further reduce disability in stroke patients; however, very few studies investigating this therapy have been conducted to date. Therefore, this study aimed to further confirm the efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke. Methods: Patients with acute ischemic stroke were administered an intravenous infusion of 320 mg cinepazide maleate or placebo once daily for 14 days. All patients were also administered basic therapy (citicoline sodium). The primary efficacy endpoint was the proportion of patients with a modified Rankin scale (mRS) ≤2 on day 90. Secondary efficacy endpoints included Barthel Index ≥95. Safety was evaluated by recording all adverse events (AEs), monitoring laboratory parameters and vital signs, and electrocardiogram. Results: In total, 937 patients with an acute ischemic stroke were included, with a mean (standard deviation, SD) National Institutes of Health Stroke Scale score of 8.8 (2.4) and a mean (SD) stroke onset of 30.9 (11.4) hours prior. Following treatment for 90 days, the proportion of patients with an mRS score ≤ 2 was significantly higher in the cinepazide maleate group than in the control group (60.9% vs. 50.1%; p = 0.0004). Moreover, the proportion of patients with a Barthel Index of ≥95 on day 90 was also significantly higher in the cinepazide maleate group than in the control group (53.4% vs. 46.7%; p = 0.0230). There were no statistically significant differences in safety parameters between the cinepazide maleate and control groups. Conclusions: The results of this study show that cinepazide maleate injection is superior to placebo in improving neurological function and activities of daily living, reducing disability, and promoting functional recovery in patients with acute ischemic stroke. Cinepazide maleate injection was safe and well tolerated with no unexpected AEs reported. Trial registration: Chinese Clinical Trial Registry CTR20160292 and ChiCTR1900023827 . Retrospectively registered June 13, 2019.